SCHEMBL5536640

SCHEMBL5536640

Oc1ccc(N2CCC(Nc3ccc(Cl)cc3Cl)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.48
CNR2 P34972 2/20 0.48
CA12 O43570 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
MAPT P10636 3/20 0.43
MAPK1 P28482 1/20 0.43
ME3 Q16798 2/20 0.42
ME2 P23368 1/20 0.41
ME1 P48163 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
USP30 Q70CQ3 1/20 0.40
UBE2M P61081 1/20 0.40
DCUN1D1 Q96GG9 1/20 0.40
SERPINE1 P05121 2/20 0.40
RAB9A P51151 1/20 0.40
LMNA P02545 3/20 0.40
ALDH1A1 P00352 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536635 0.86 MAPT (0.41) CNR1CNR2KMT2AMEN1MAPT
SCHEMBL5536343 0.83 ME3 (0.50) CNR1CNR2CA12CA2CA9
SCHEMBL5537275 0.80 CA12 (0.58) CNR1CNR2CA12CA2CA9
SCHEMBL2092303 0.79 CNR1 (0.48) CNR1CNR2CA12CA2CA9
SCHEMBL5543886 0.78 ME3 (0.45) CNR1CNR2CA12CA2CA9
SCHEMBL1159931 0.77 RAB9A (0.50) KMT2AMEN1MAPTMAPK1USP30
SCHEMBL2093899 0.77 MAPT (0.47) CNR1CNR2CA12CA2CA9
SCHEMBL7794566 0.74 RAB9A (0.59) KMT2AMEN1MAPTMAPK1RAB9A
SCHEMBL29264920 0.74 S1PR1 (0.48) CA12CA2CA9KMT2AMEN1
SCHEMBL7794045 0.73 RAB9A (0.48) KMT2AMEN1MAPTMAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CNR1 857/4885CNR2 1408/4885CA12 1998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.